Skip to main content
Top
Published in: Diabetologia 9/2010

01-09-2010 | Short Communication

Aberrant hepatic TRIB3 gene expression in insulin-resistant obese humans

Authors: H. Oberkofler, A. Pfeifenberger, S. Soyal, T. Felder, P. Hahne, K. Miller, F. Krempler, W. Patsch

Published in: Diabetologia | Issue 9/2010

Login to get access

Abstract

Aims/hypothesis

The pseudokinase tribbles homologue 3 (Drosophila) (TRIB3) negatively interferes with insulin-mediated phosphorylation and activation of v-akt murine thymoma viral oncogene homologue 1 (AKT1, also known as protein kinase B). Animal studies have shown that Trib3 expression was higher in the fasting state and in animal models of diabetes, promoting hyperglycaemia presumably by increasing glucose production in the liver. Less is known about the role of TRIB3 in insulin resistance in humans, although a gain-of-function mutation associated with abnormalities related to insulin resistance has been described in TRIB3.

Methods

We determined hepatic mRNA expression of TRIB3 and selected genes encoding enzymes, transcription factors and coactivators involved in glucose homeostasis. We also determined biochemical variables of intermediary metabolism in obese patients with varying degrees of insulin resistance.

Results

In our study population hepatic TRIB3 mRNA expression was associated with surrogate markers of insulin resistance. TRIB3 expression was significantly increased in a subgroup with high HOMA of insulin resistance (HOMA-IR) compared with a low HOMA-IR group (p = 0.0033). TRIB3 transcript levels were correlated with PEPCK (also known as PCK2) mRNA expression (p = 0.0014) and mRNA expression of PPARGC1A (p = 0.0020), PPARGC1B (p < 0.0001), USF1 (p = 0.0017), FOXO1 (p = 0.0003) and SREBP-1c (also known as SREBF1; p = 0.0360). Furthermore ligands of peroxisome proliferator-activated receptor α/retinoid X receptor and overexpression of its coactivator PPARGC1A as well as overexpression of SREBP-1c and its coactivator PPARGC1B increased TRIB3 promoter activity in HepG2 cells.

Conclusions/interpretation

We have found evidence for a role of aberrant hepatic TRIB3 transcript levels in insulin resistance in obese humans and identified potential transcriptional pathways involved in regulation of TRIB3 gene expression in the liver.
Appendix
Available only for authorised users
Literature
1.
go back to reference Du K, Herzig S, Kulkarni RN, Montminy M (2003) TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300:1574–1577CrossRefPubMed Du K, Herzig S, Kulkarni RN, Montminy M (2003) TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300:1574–1577CrossRefPubMed
2.
go back to reference He L, Simmen FA, Mehendale HM, Ronis MJ, Badger TM (2006) Chronic ethanol intake impairs insulin signaling in rats by disrupting Akt association with the cell membrane. Role of TRB3 in inhibition of Akt/protein kinase B activation. J Biol Chem 281:11126–11134CrossRefPubMed He L, Simmen FA, Mehendale HM, Ronis MJ, Badger TM (2006) Chronic ethanol intake impairs insulin signaling in rats by disrupting Akt association with the cell membrane. Role of TRB3 in inhibition of Akt/protein kinase B activation. J Biol Chem 281:11126–11134CrossRefPubMed
3.
go back to reference Okamoto H, Latres E, Liu R et al (2007) Genetic deletion of Trb3, the mammalian Drosophila tribbles homolog, displays normal hepatic insulin signaling and glucose homeostasis. Diabetes 56:1350–1356CrossRefPubMed Okamoto H, Latres E, Liu R et al (2007) Genetic deletion of Trb3, the mammalian Drosophila tribbles homolog, displays normal hepatic insulin signaling and glucose homeostasis. Diabetes 56:1350–1356CrossRefPubMed
4.
go back to reference Iynedjian PB (2005) Lack of evidence for a role of TRB3/NIPK as an inhibitor of PKB-mediated insulin signalling in primary hepatocytes. Biochem J 386:113–118CrossRefPubMed Iynedjian PB (2005) Lack of evidence for a role of TRB3/NIPK as an inhibitor of PKB-mediated insulin signalling in primary hepatocytes. Biochem J 386:113–118CrossRefPubMed
5.
go back to reference Koo SH, Satoh H, Herzig S et al (2004) PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 10:530–534CrossRefPubMed Koo SH, Satoh H, Herzig S et al (2004) PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 10:530–534CrossRefPubMed
6.
go back to reference Cheng KK, Iglesias MA, Lam KS et al (2009) APPL1 potentiates insulin-mediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice. Cell Metab 9:417–427CrossRefPubMed Cheng KK, Iglesias MA, Lam KS et al (2009) APPL1 potentiates insulin-mediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice. Cell Metab 9:417–427CrossRefPubMed
7.
go back to reference Prudente S, Hribal ML, Flex E et al (2005) The functional Q84R polymorphism of mammalian Tribbles homolog TRB3 is associated with insulin resistance and related cardiovascular risk in Caucasians from Italy. Diabetes 54:2807–2811CrossRefPubMed Prudente S, Hribal ML, Flex E et al (2005) The functional Q84R polymorphism of mammalian Tribbles homolog TRB3 is associated with insulin resistance and related cardiovascular risk in Caucasians from Italy. Diabetes 54:2807–2811CrossRefPubMed
8.
go back to reference Andreozzi F, Formoso G, Prudente S et al (2008) TRIB3 R84 variant is associated with impaired insulin-mediated nitric oxide production in human endothelial cells. Arterioscler Thromb Vasc Biol 28:1355–1360CrossRefPubMed Andreozzi F, Formoso G, Prudente S et al (2008) TRIB3 R84 variant is associated with impaired insulin-mediated nitric oxide production in human endothelial cells. Arterioscler Thromb Vasc Biol 28:1355–1360CrossRefPubMed
9.
go back to reference Felder T, Hahne P, Soyal SM et al. (2010) Hepatic adiponectin receptors (ADIPOR) 1 and 2 mRNA and their relation to insulin resistance in obese humans. Int J Obes (Lond). doi:10.1038/ijo.2010.7 Felder T, Hahne P, Soyal SM et al. (2010) Hepatic adiponectin receptors (ADIPOR) 1 and 2 mRNA and their relation to insulin resistance in obese humans. Int J Obes (Lond). doi:10.​1038/​ijo.​2010.​7
10.
go back to reference Oberkofler H, Hafner M, Felder T, Krempler F, Patsch W (2009) Transcriptional co-activator peroxisome proliferator-activated receptor (PPAR) gamma co-activator-1beta is involved in the regulation of glucose-stimulated insulin secretion in INS-1E cells. J Mol Med 87:299–306CrossRefPubMed Oberkofler H, Hafner M, Felder T, Krempler F, Patsch W (2009) Transcriptional co-activator peroxisome proliferator-activated receptor (PPAR) gamma co-activator-1beta is involved in the regulation of glucose-stimulated insulin secretion in INS-1E cells. J Mol Med 87:299–306CrossRefPubMed
11.
go back to reference Lin J, Yang R, Tarr PT et al (2005) Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120:261–273CrossRefPubMed Lin J, Yang R, Tarr PT et al (2005) Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120:261–273CrossRefPubMed
12.
go back to reference Kammoun HL, Chabanon H, Hainault I et al (2009) GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 119:1201–1215CrossRefPubMed Kammoun HL, Chabanon H, Hainault I et al (2009) GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 119:1201–1215CrossRefPubMed
Metadata
Title
Aberrant hepatic TRIB3 gene expression in insulin-resistant obese humans
Authors
H. Oberkofler
A. Pfeifenberger
S. Soyal
T. Felder
P. Hahne
K. Miller
F. Krempler
W. Patsch
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1772-2

Other articles of this Issue 9/2010

Diabetologia 9/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.